Sensorion takes a key step towards phase 2 with SENS-401 thanks to the positive results obtained in the phase 1 clinical trial

Read

Sensorion Presents Preclinical Data for SENS-401 Demonstrating Protection against Cisplatin-Induced Hearing Loss in Animal Model

Read

Intensification of the Company’s international development with the appointment of a new CEO 

Read

Sensorion reports full year 2016 results in line with status of clinical development

Read

Sensorion receives European authorization to initiate Phase II clinical trial of SENS-111 to treat acute vertigo

Read

Pipeline

2018 08 Pipeline

Enregistrer

Patient center

Corporate presentation

Next events